donepezil has been researched along with Prodromal Characteristics in 5 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD)." | 9.20 | Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. ( Ait Ameur, A; Bonafe, A; Cavedo, E; Ceccaldi, M; Chupin, M; Colliot, O; Croisile, B; Delmaire, C; Dormont, D; Dubois, B; Dufouil, C; Duveau, F; Garnero, L; Girard, N; Hampel, H; Lehericy, S; Lista, S; Louis Tisserand, G; Ousset, PJ; Pasquier, F; Ricolfi, F; Rouaud, O; Sarazin, M; Tonelli, I; Touchon, J; Vighetto, A, 2015) |
| "Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2)." | 6.84 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. ( Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Grothe, MJ; Hampel, H; Houot, M; Lehéricy, S; Lista, S; Teipel, S, 2017) |
| "We determined the value of hippocampus (Hp) and basal forebrain (BF) volumes for predicting cognitive decline and treatment response in a double-blind, randomized, placebo-controlled phase 4 trial at 28 academic centers (France) in patients with amnestic mild cognitive impairment (MCI) receiving Donepezil 10 mg daily or placebo over 12 months, and 6 months open label follow-up." | 5.22 | Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease. ( Bakardjian, H; Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Galluzzi, S; Grothe, MJ; Hampel, H; Lista, S; Teipel, SJ, 2016) |
| "The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD)." | 5.20 | Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. ( Ait Ameur, A; Bonafe, A; Cavedo, E; Ceccaldi, M; Chupin, M; Colliot, O; Croisile, B; Delmaire, C; Dormont, D; Dubois, B; Dufouil, C; Duveau, F; Garnero, L; Girard, N; Hampel, H; Lehericy, S; Lista, S; Louis Tisserand, G; Ousset, PJ; Pasquier, F; Ricolfi, F; Rouaud, O; Sarazin, M; Tonelli, I; Touchon, J; Vighetto, A, 2015) |
| "Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2)." | 2.84 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. ( Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Grothe, MJ; Hampel, H; Houot, M; Lehéricy, S; Lista, S; Teipel, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, GW | 1 |
| Kim, BC | 1 |
| Park, KS | 1 |
| Jeong, GW | 1 |
| Cavedo, E | 4 |
| Grothe, MJ | 2 |
| Colliot, O | 4 |
| Lista, S | 4 |
| Chupin, M | 4 |
| Dormont, D | 4 |
| Houot, M | 1 |
| Lehéricy, S | 3 |
| Teipel, S | 1 |
| Dubois, B | 4 |
| Hampel, H | 4 |
| Croisile, B | 2 |
| Louis Tisserand, G | 1 |
| Touchon, J | 2 |
| Bonafe, A | 2 |
| Ousset, PJ | 2 |
| Ait Ameur, A | 1 |
| Rouaud, O | 2 |
| Ricolfi, F | 2 |
| Vighetto, A | 2 |
| Pasquier, F | 2 |
| Delmaire, C | 2 |
| Ceccaldi, M | 2 |
| Girard, N | 2 |
| Dufouil, C | 1 |
| Tonelli, I | 1 |
| Duveau, F | 2 |
| Garnero, L | 1 |
| Sarazin, M | 2 |
| Teipel, SJ | 1 |
| Galluzzi, S | 2 |
| Bakardjian, H | 1 |
| Tisserand, GL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias[NCT02921477] | Phase 1 | 150 participants (Anticipated) | Interventional | 2016-09-30 | Enrolling by invitation | ||
| Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders[NCT00403520] | Phase 4 | 240 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for donepezil and Prodromal Characteristics
| Article | Year |
|---|---|
Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Basal Forebrain; Cholinergic Neurons; Disease Progression; Donepez | 2017 |
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Disease Progression; Donepezil; Double-Blind Method; Female; Franc | 2015 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Predictors of cognitive decline and treatment response in a clinical trial on suspected prodromal Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Dysfunction; Cross-Sectional Studies; Disease | 2016 |
Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Cerebral Cortex; Cognitive Dysfunction; Disease | 2016 |
1 other study available for donepezil and Prodromal Characteristics
| Article | Year |
|---|---|
A pilot study of brain morphometry following donepezil treatment in mild cognitive impairment: volume changes of cortical/subcortical regions and hippocampal subfields.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cerebral Cortex; Cognitive Dysfunction; Disease P | 2020 |